EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Substantial early venous thromboembolism risk with amivantamab plus lazertinib and potential mitigation strategies

Samer Salem, Keith R. McCrae, Alok A. Khorana

Blood Vessels, Thrombosis & Hemostasis · 2026-11 · 100237

DOI: 10.1016/j.bvth.2026.100237 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Blood Vessels, Thrombosis & Hemostasis, 2026-11. Verfasst von Samer Salem und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Salem, S., McCrae, K. R., & Khorana, A. A. (2026). Substantial early venous thromboembolism risk with amivantamab plus lazertinib and potential mitigation strategies. Blood Vessels, Thrombosis & Hemostasis, 100237. https://doi.org/10.1016/j.bvth.2026.100237

Vancouver

Salem S, McCrae KR, Khorana AA. Substantial early venous thromboembolism risk with amivantamab plus lazertinib and potential mitigation strategies. Blood Vessels, Thrombosis & Hemostasis. 2026:100237. doi:10.1016/j.bvth.2026.100237

BibTeX
@article{Salem2026,
  author = {Salem, Samer and McCrae, Keith R. and Khorana, Alok A.},
  title = {Substantial early venous thromboembolism risk with amivantamab plus lazertinib and potential mitigation strategies},
  journal = {Blood Vessels, Thrombosis & Hemostasis},
  year = {2026},
  pages = {100237},
  doi = {10.1016/j.bvth.2026.100237}
}
Kostenlos starten →